Hampel, Harald http://orcid.org/0000-0003-0894-8982
Au, Rhoda
Mattke, Soeren http://orcid.org/0000-0003-4666-9132
van der Flier, Wiesje M. http://orcid.org/0000-0001-8766-6224
Aisen, Paul
Apostolova, Liana
Chen, Christopher
Cho, Min
De Santi, Susan
Gao, Peng
Iwata, Atsushi
Kurzman, Ricky
Saykin, Andrew J. http://orcid.org/0000-0002-1376-8532
Teipel, Stefan
Vellas, Bruno
Vergallo, Andrea
Wang, Huali
Cummings, Jeffrey
Article History
Received: 7 March 2022
Accepted: 7 July 2022
First Online: 19 August 2022
Competing interests
: H.H. is an employee of Eisai and serves as senior associate editor for the Journal Alzheimer’s & Dementia and has not received any fees or honoraria since May 2019. H.H. is inventor of 11 patents and has received no royalties for: In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders patent no. 8916388; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases patent no. 8298784; Neurodegenerative Markers for Psychiatric Conditions publication no. 20120196300; In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders publication no. 20100062463; In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders publication no. 20100035286; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases publication no. 20090263822; In Vitro Method for The Diagnosis of Neurodegenerative Diseases patent no. 7547553; CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases publication no. 20080206797; In Vitro Method for The Diagnosis of Neurodegenerative Diseases publication no. 20080199966; Neurodegenerative Markers for Psychiatric Conditions publication no. 20080131921; Method for diagnosis of dementias and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid: US patent no. 10921330. R.A. is a scientific advisor to Signant Health and consultant to Biogen. S.M. serves on the board of directors of Senscio Systems and the scientific advisory board of AiCure Technologies, and Boston Millennia Partners, and has received consulting fees from AARP, Biogen, Biotronik, Bristol-Myers Squibb, C2N, Eisai and Roche. Research programs of W.M.v.d.F. have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Biogen MA, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm and Combinostics. W.F. holds the Pasman chair. W.F. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance, LSHM20106). W.F. has performed contract research for Biogen MA and Boehringer Ingelheim. W.F. has been an invited speaker at Boehringer Ingelheim, Biogen MA, Danone, Eisai, WebMD Neurology (Medscape) and Springer Healthcare. W.F. is consultant to Oxford Health Policy Forum CIC, Roche and Biogen MA. W.F. participated in advisory boards of Biogen MA and Roche. All funding is paid to the institution of W.F. W.F. was associate editor of Alzheimer, Research & Therapy in 2020/2021. W.F. is associate editor at Brain. P.A. reports research agreements with Janssen, Lilly and Eisai, grants from NIA, the Alzheimer’s Association and FNIH and consulting fees from Biogen, Roche, Merck, Abbvie, Immunobrain Checkpoint, Rainbow Medical and Shionogi. L.A. has provided consultation to Eli Lilly, Biogen, Eisai, GE Healthcare and Two Labs. L.G.A. receives research support from NIA U01 AG057195, NIA R01 AG057739, NIA P30 AG010133, Alzheimer Association LEADS GENETICS 19-639372, Roche Diagnostics RD005665, AVID Pharmaceuticals and Life Molecular Imaging. L.G.A. received honoraria for participating in independent data safety monitoring boards and providing educational CME lectures and programs. L.G.A. has stock in Cassava Sciences and Semiring. C.C. receives research grants from the National Medical Research Council of Singapore. C.C. also receives research support from Moleac, Roche, Eisai and Lundbeck; and has participated in advisory boards for Cerecin and Eisai in the past 3 years. A.I. receives research grant from AMED (Japanese Agency for Medical Research), JSPS (Japan Society for Promotion of Science), Eisai, Daiichi Sankyo, Shionogi, Chugai-Roche and Kyowa Kirin. A.I. also receives consultant fees from Eisai, Biogen and Janssen Pharmaceuticals. A.I. also receives lecture fees from Eisai, Daiichi Sankyo, Otsuka, Ono Pharmaceutical and Fujirebio. A.S. received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor), Bayer Oncology (Scientific Advisory Board), Eisai (Scientific Advisory Board), Siemens Medical Solutions USA (Dementia Advisory Board) and Springer Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). S.T. has served on the advisory boards of Roche, Biogen, Eisai and Grifols within the last 3 years. B.V. has served as consultant/advisor to Eisai, Biogen, Lilly, Longeveron, Novo Nordisk, TauRx P and Roche in the past 3 years. A.V. declares no competing interests related to the present paper and the contribution of A.V. to this paper reflects entirely and only A.V.’s own academic expertise on the matter. A.V. was an employee of Eisai (November 2019–June 2021). A.V. did not receive any fees or honoraria since November 2019. Before November 2019, A.V. received lecture honoraria from Roche, MagQu and Servier. H.W. has provided consultation to Eisai, Lundbeck, Roche and Signant Health pharmaceutical and assessment companies. H.W. owns the copyright of the individualized management system of neuropsychiatric symptoms (NPSIMS) and the smartphone-based application of brief cognitive screening kit (shairenzhi). J.C. provided consultation to AB Science, Acadia, Alkahest, AlphaCognition, ALZPathFinder, Annovis, AriBio, Artery, Avanir, Biogen, Biosplice, Cassava, Cerevel, Clinilabs, Cortexyme, Diadem, EIP Pharma, Eisai, GatehouseBio, GemVax, Genentech, Green Valley, Grifols, Janssen, Karuna, Lexeo, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Ono, Otsuka, PharmacotrophiX, PRODEO, Prothena, ReMYND, Renew, Resverlogix, Roche, Signant Health, Suven, Unlearn AI, Vaxxinity, VigilNeuro pharmaceutical, assessment and investment companies. M.C., S.D.S., P.G. and R.K. are employees of Eisai.
Free to read: This content has been made available to all.